6,075,331 Shares in Edgewise Therapeutics, Inc. $EWTX Acquired by Jupiter Topco LLC

Posted by Francis Steltz on Aug 27th, 2026

Jupiter Topco LLC acquired a new position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,075,331 shares of the company’s stock, valued at approximately $246,945,000. Jupiter Topco LLC owned approximately 0.06% of Edgewise Therapeutics as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in EWTX. J. Goldman & Co LP acquired a new position in shares of Edgewise Therapeutics during the 2nd quarter valued at $414,000. ADAR1 Capital Management LLC acquired a new stake in Edgewise Therapeutics in the 2nd quarter valued at $5,818,000. Hsbc Holdings PLC acquired a new stake in Edgewise Therapeutics in the 2nd quarter valued at $3,723,000. Parkman Healthcare Partners LLC purchased a new position in Edgewise Therapeutics in the second quarter valued at about $23,445,000. Finally, Legal & General Group Plc purchased a new position in Edgewise Therapeutics in the second quarter valued at about $1,816,000.

Insiders Place Their Bets

In related news, General Counsel John R. Moore sold 5,016 shares of the stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $43.82, for a total value of $219,801.12. Following the completion of the transaction, the general counsel owned 17,697 shares of the company’s stock, valued at approximately $775,482.54. This represents a 22.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Kevin Koch sold 17,971 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $43.68, for a total value of $784,973.28. Following the sale, the chief executive officer owned 52,488 shares of the company’s stock, valued at approximately $2,292,675.84. This trade represents a 25.51% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 238,329 shares of company stock worth $9,557,529. 21.30% of the stock is owned by insiders.

Edgewise Therapeutics Price Performance

Edgewise Therapeutics stock opened at $44.38 on Thursday. Edgewise Therapeutics, Inc. has a 12-month low of $13.69 and a 12-month high of $48.40. The company has a market capitalization of $4.82 billion, a price-to-earnings ratio of -23.99 and a beta of 0.30. The firm’s fifty day moving average price is $41.73 and its 200 day moving average price is $35.55.

Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06). Analysts forecast that Edgewise Therapeutics, Inc. will post -2.09 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on EWTX. Oppenheimer started coverage on Edgewise Therapeutics in a research note on Thursday, July 9th. They set an “outperform” rating and a $51.00 price objective on the stock. Truist Financial set a $52.00 target price on Edgewise Therapeutics in a research note on Wednesday, May 6th. Raymond James Financial reiterated a “strong-buy” rating and set a $66.00 target price on shares of Edgewise Therapeutics in a report on Monday, June 1st. Royal Bank Of Canada boosted their price target on Edgewise Therapeutics from $48.00 to $59.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 17th. Finally, Leerink Partners set a $52.00 price target on Edgewise Therapeutics in a report on Tuesday, June 16th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $50.33.

View Our Latest Research Report on Edgewise Therapeutics

About Edgewise Therapeutics

(Free Report)

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.